These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 27475662)

  • 1. The Economic Burden of Chronic Kidney Disease and End-Stage Renal Disease.
    Wang V; Vilme H; Maciejewski ML; Boulware LE
    Semin Nephrol; 2016 Jul; 36(4):319-30. PubMed ID: 27475662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
    Kent S; Schlackow I; Lozano-Kühne J; Reith C; Emberson J; Haynes R; Gray A; Cass A; Baigent C; Landray MJ; Herrington W; Mihaylova B;
    BMC Nephrol; 2015 Apr; 16():65. PubMed ID: 25924679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-cause costs increase exponentially with increased chronic kidney disease stage.
    Golestaneh L; Alvarez PJ; Reaven NL; Funk SE; McGaughey KJ; Romero A; Brenner MS; Onuigbo M
    Am J Manag Care; 2017 Jun; 23(10 Suppl):S163-S172. PubMed ID: 28978205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes.
    Vupputuri S; Kimes TM; Calloway MO; Christian JB; Bruhn D; Martin AA; Nichols GA
    J Diabetes Complications; 2014; 28(1):10-6. PubMed ID: 24211091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review.
    Elshahat S; Cockwell P; Maxwell AP; Griffin M; O'Brien T; O'Neill C
    PLoS One; 2020; 15(3):e0230512. PubMed ID: 32208435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effective treatment modalities for reducing morbidity associated with chronic kidney disease.
    Ferguson TW; Tangri N; Rigatto C; Komenda P
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):243-52. PubMed ID: 25661187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of chronic kidney disease attributable to diabetes from the perspective of the Brazilian Unified Health System.
    Goncalves GMR; Silva END
    PLoS One; 2018; 13(10):e0203992. PubMed ID: 30273345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost to government and society of chronic kidney disease stage 1-5: a national cohort study.
    Wyld ML; Lee CM; Zhuo X; White S; Shaw JE; Morton RL; Colagiuri S; Chadban SJ
    Intern Med J; 2015 Jul; 45(7):741-7. PubMed ID: 25944415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme.
    Jha V; Al-Ghamdi SMG; Li G; Wu MS; Stafylas P; Retat L; Card-Gowers J; Barone S; Cabrera C; Garcia Sanchez JJ
    Adv Ther; 2023 Oct; 40(10):4405-4420. PubMed ID: 37493856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect costs and public finance consequences of heart failure in Poland, 2012-2015.
    Łyszczarz B
    BMC Public Health; 2018 Sep; 18(1):1130. PubMed ID: 30231932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct non-medical and indirect costs of diabetes and its associated complications in Vietnam: an estimation using national health insurance claims from a cross-sectional survey.
    Kieu TTM; Trinh HN; Pham HTK; Nguyen TB; Ng JYS
    BMJ Open; 2020 Mar; 10(3):e032303. PubMed ID: 32132135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
    Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
    J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden of chronic kidney disease in Korea using national sample cohort.
    Kim SH; Jo MW; Go DS; Ryu DR; Park J
    J Nephrol; 2017 Dec; 30(6):787-793. PubMed ID: 28303461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From CKD to ESRD: a tale of two transitions.
    Kossmann RJ
    Adv Chronic Kidney Dis; 2011 Nov; 18(6):439-42. PubMed ID: 22098663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic burden of end-stage renal disease in Canada.
    Zelmer JL
    Kidney Int; 2007 Nov; 72(9):1122-9. PubMed ID: 17700643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical costs of CKD in the Medicare population.
    Honeycutt AA; Segel JE; Zhuo X; Hoerger TJ; Imai K; Williams D
    J Am Soc Nephrol; 2013 Sep; 24(9):1478-83. PubMed ID: 23907508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Issues of Chronic Kidney Disease and End-Stage Renal Disease.
    Takemoto Y; Naganuma T
    Contrib Nephrol; 2019; 198():87-93. PubMed ID: 30991413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projection of the health and economic impacts of Chronic kidney disease in the Chilean population.
    Walbaum M; Scholes S; Rojas R; Mindell JS; Pizzo E
    PLoS One; 2021; 16(9):e0256680. PubMed ID: 34495980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A contemporary evaluation of carotid endarterectomy outcomes in patients with chronic kidney disease in the United States.
    Patel AR; Dombrovskiy VY; Vogel TR
    Vascular; 2017 Oct; 25(5):459-465. PubMed ID: 28181855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis.
    Roggeri A; Roggeri DP; Zocchetti C; Bersani M; Conte F; ;
    J Nephrol; 2017 Apr; 30(2):263-269. PubMed ID: 27165160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.